Company intelligence / Profile preview

Tellus Remedy

Durham, North Carolina, United Statesvtext.valdosta.edu ↗

Ownership: Private
Development stage: Other

Overview

Tellus Therapeutics is developing TT-20, a novel small molecule derived from human breast milk, to promote myelination and repair white matter injury in premature infants. Preclinical studies have shown efficacy and safety in animal models, with the goal of preventing neurodevelopmental disabilities such as cerebral palsy. The company has secured seed funding and plans to advance into clinical trials targeting newborns at risk for brain injury.

Therapeutic areas: Neurology
Modalities: Small moleculeLipid molecule
Industry: Biotech

Partnerships

Xontogeny LLC (seed investment and advisory support)

Beyond the preview

Go deeper on Tellus Remedy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tellus Remedy.

Explore the full profile